evidence: RNA vaccines 2020 has witnessed unprecedented situations due to coronavirus pandemic that affected all aspects of life. The whole globe lived months of uncertainty before two companies have announced the incredible results of phase III clinical trials for two different mRNA-based vaccines. [...] Having said that, both mRNA-based vaccines represent a unique case that is considered one of the most advanced and promising achievements in the field of pharmaceutical biotechnology and biopharmaceutical formulations. More than three decades of research effort on developing gene therapy solutions for many diseases could not convey many healthcare policymakers, pharmaceutical companies, funding agencies, medicine agencies, and drug administrations to adopt gene therapy avenues as highly potential approaches to transfer the therapeutic strategies into a new era. However, these mRNA vaccines, which have been developed and approved within a few months, signify a breakthrough in the field of gene therapy, which has battled to achieve ordinary acknowledgement due to a large number of sceptical and conservative scientists and other claimed safety and translational concerns. Although these two vaccines are not the first approved drugs utilising genetic materials as active ingredients, they are believed to be a milestone in modern medical history that may forever change pharmaceutical approaches. [...] Unlike other vaccines, mRNA vaccines are flexible and adaptable; they can be modified to suit different emergent variants in a very short time with minimum effort. The lipid carriers can be used for the coming vaccines with changes in the mRNA sequence only. mRNA sequencing is not a complicated process and can be performed within weeks, according to Ugur Shahin, the CEO and co-founder of BioNtech.